Pulse ·

Prostate cancer testing now starts at 45 for higher-risk Australians

By Dr HB Lo, FACRRM 5 min read
Verdict Yes — worth knowing about

Australia's first major prostate cancer guideline update in a decade recommends PSA testing every two years for men aged 50–69. Three higher-risk groups — significant family history, sub-Saharan African ancestry over 45, or confirmed BRCA2 mutation — are advised to start at age 45.

The pathway has also shifted: MRI now typically precedes biopsy, cutting unnecessary procedures. For low-risk disease, active surveillance — monitoring without immediate treatment — is the recommended approach, used in over 80% of low-risk cases. Every step requires informed, shared decision-making.

What just happened

Australia’s first major prostate cancer detection guideline update in a decade landed this week, and the RACGP has formally endorsed it.

The core change is the age at which higher-risk men are offered PSA testing: down from 50 to 45. The guideline, developed by the Prostate Cancer Foundation of Australia and approved by the NHMRC, identifies three groups at substantially elevated risk — at least double the population average. Men over 45 with a significant family history of prostate cancer. Men of sub-Saharan African ancestry over 45. Men over 45 with a confirmed BRCA2 gene mutation. All three groups are now explicitly advised to have the testing conversation with their GP before the standard age-50 threshold.

For standard-risk men aged 50–69, the recommendation remains: PSA testing every two years, for those who choose to be tested after a full discussion of benefits and harms.

Prostate cancer is Australia’s most commonly diagnosed cancer — approximately 29,000 new diagnoses and 4,000 deaths in 2025. Survivability is high when caught early. The question the guideline tries to resolve is who to look for it in, when, and how — without creating a conveyor belt of overdiagnosis and overtreatment for slow-growing cancers that pose no real threat.

If you are reading this and thinking “that’s not really about me” — it might not be directly. But many of the people in your life sit in those higher-risk definitions without knowing it, and this week’s news is the prompt they need.

Both-and

The guideline represents a real improvement

Two changes here matter more than the headline age shift.

The first is the move to MRI before biopsy. The previous clinical pathway often moved straight from an elevated PSA to tissue biopsy — a procedure that is uncomfortable, carries infection risk, and has historically turned up a large proportion of clinically insignificant cancers that then triggered anxiety, further investigation, and sometimes treatment that was never warranted. Under the updated approach, an MRI scan typically characterises the lesion first, before any biopsy decision is made.

Dr Brett Montgomery, the RACGP’s representative on the guideline steering committee, explained the shift: “MRI scanning now precedes biopsy decisions, helping avoid biopsies that aren’t really necessary.” That is a meaningful change in patient experience, downstream resource use, and — for the subset of men who would have received unnecessary biopsies — a real reduction in harm.

The second is the formalisation of active surveillance for low-risk disease. Over 80% of men diagnosed with lower-risk prostate cancer are now recommended for regular monitoring rather than immediate surgery or radiation. The guideline acknowledges what urologists have been moving toward in practice for years: that catching a cancer early does not automatically mean treating it immediately. Active surveillance preserves all treatment options while protecting quality of life during a period when intervention carries more risk than watching closely.

Federal Health Minister Mark Butler announced $320,000 to the RACGP to develop GP education programs specifically around supporting patients through these decisions — a signal that the government recognises this is a conversation-intensive guideline, not a tick-box one.

PSA is still an imperfect test

PSA (prostate-specific antigen) is not a cancer-specific marker. It rises in benign prostate enlargement, prostatitis, and after physical exertion or sexual activity. It can also be within the normal range in men who do have prostate cancer. The guideline’s repeated emphasis on informed consent before testing reflects this — the words “again and again” appear in Dr Montgomery’s description of how often the guideline returns to the importance of pre-test discussion.

This is not a screening test you simply order. It is a conversation about what the test can and cannot tell you, what the downstream pathway looks like if results are abnormal, and whether that pathway aligns with the individual man’s values and circumstances. A man who understands the limitations of PSA is in a fundamentally better position to make decisions about investigation and treatment than one who received a result without that context.

The upper age limit question has also been refined. The guideline removes a fixed upper cutoff and replaces it with individualised assessment: continue offering PSA testing to men over 70 when life expectancy exceeds seven years and comorbidities are manageable. Stop when limited life expectancy or significant comorbidities mean that treatment — even if cancer is found — would be unlikely to add quality or length of life. Men over 70 with a PSA below 5.5 µg/L may also reasonably discontinue testing. These are clinical conversations, not automatic decisions.

Why this matters to women too — the BRCA2 thread

BRCA2 is known primarily as a breast and ovarian cancer risk gene. It is also a prostate cancer risk gene. Men with a confirmed BRCA2 mutation face substantially elevated risk — high enough to be included in this guideline’s age-45 testing threshold.

If there is a BRCA2 mutation in your family — your own testing, a first-degree relative’s result — that conversation belongs to the male members of your family too. It is worth raising with your GP whether family history, including BRCA2 status, warrants a referral for genetic counselling that considers the full family picture, not just the female side of it.

My two cents

The change that matters most this week is the earlier threshold for higher-risk men. If there is a man over 45 in your life with a significant family history of prostate cancer, or who knows he is of sub-Saharan African ancestry, or who has been tested for BRCA2 — these guidelines mean his conversation with a GP about PSA testing is now, not at 50.

For the man at standard risk: the guideline supports being offered testing from 50 with full information. The choice remains his. What has changed is the clarity around who needs that choice earlier.

For anyone who has been in the diagnostic process — elevated PSA, awaiting biopsy, managing a previous low-risk diagnosis — the MRI-before-biopsy approach and the formalisation of active surveillance are worth discussing with your urologist in light of these updated recommendations.

Verdict: yes — worth knowing about, particularly for anyone with family history, BRCA2 relevance, or a male over 45 in their life who hasn’t had this conversation yet.

Sources cited

  1. RACGP endorses updated prostate cancer guideline. newsGP, 10 August 2026. https://www1.racgp.org.au/newsgp/clinical/racgp-endorses-updated-prostate-cancer-guideline
  2. Offer prostate cancer testing every two years from age 45 for higher-risk men: new Aussie guidelines. AusDoc, 11 August 2026. https://www.ausdoc.com.au/news/start-prostate-cancer-testing-every-two-years-at-age-45-for-higher-risk-men-new-aussie-guidelines/
  3. Prostate Cancer Foundation of Australia. https://www.pcfa.org.au

Frequently asked questions

  • Who counts as higher-risk for prostate cancer in Australia?

    The updated guidelines define three groups at least double the population average risk: men over 45 with a significant family history of prostate cancer, men of sub-Saharan African ancestry over 45, and men over 45 with a confirmed BRCA2 gene mutation. If you or a family member fall into one of those groups, a conversation with a GP about whether to start testing is worth having before age 50.

  • What does active surveillance mean for a man diagnosed with low-risk prostate cancer?

    Active surveillance means regular monitoring — PSA tests, repeat MRI, sometimes repeat biopsies over time — without immediate surgery or radiation. It is now the preferred approach for low-risk prostate cancer, where the cancer is small and slow-growing. Treating early-stage, low-risk prostate cancer often causes side effects — particularly incontinence and erectile dysfunction — that may not be justified when the cancer poses no near-term threat to life. Active surveillance preserves treatment options while avoiding unnecessary harm.